ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Povorcitinib (Povofortay)

Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In two identical phase 3 trials of 1,227 adults with moderate to severe hidradenitis suppurativa, oral povorcitinib 45 or 75 mg raised week-12 HiSCR50 vs placebo (40–42% vs 30% and 29%). Serious adverse events: 5–6% by week 54; acne was common (17–20%). RCT · phase 3 · n = 1,227 · Nat Med · 2026

CHMP opinion 17 Sept 2026 → EU licence 12 Nov 2026 · Incyte Biosciences Distribution B.V.

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.